WO1992011039A1 - Derivatized tris-catechol chelating agents - Google Patents
Derivatized tris-catechol chelating agents Download PDFInfo
- Publication number
- WO1992011039A1 WO1992011039A1 PCT/US1991/009153 US9109153W WO9211039A1 WO 1992011039 A1 WO1992011039 A1 WO 1992011039A1 US 9109153 W US9109153 W US 9109153W WO 9211039 A1 WO9211039 A1 WO 9211039A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- solution
- radiometal
- ncs
- Prior art date
Links
- 0 C*(CNC(C(CC=C(*1)C(O)=*CC[C@@](C)C**N(C)C)C1O)O)I Chemical compound C*(CNC(C(CC=C(*1)C(O)=*CC[C@@](C)C**N(C)C)C1O)O)I 0.000 description 3
- IYTRVIRNOWQFGY-FCKCIMNISA-N CC(C)CNC(C(CCC(C(NC[C@@H](C)I)O)C1O)C1O)O Chemical compound CC(C)CNC(C(CCC(C(NC[C@@H](C)I)O)C1O)C1O)O IYTRVIRNOWQFGY-FCKCIMNISA-N 0.000 description 1
- GJUAWFMCPZTPJE-UHFFFAOYSA-N CC(CCC(C(N)O)C1N=O)C1N=O Chemical compound CC(CCC(C(N)O)C1N=O)C1N=O GJUAWFMCPZTPJE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- the present invention relates to novel "bifunctionai" chelating agents. More specifically, the present invention relates to bifunctionai chelating agents which are designed to sequester certain radioactive metals and to provide a means for covalently attaching these radionuclides to a macromolecule, such as an antibody.
- the invention further relates to methods for preparing these compounds as well as methods of using these compounds in radioimmunoimaging, positron emission tomography and in vivo treatment.
- the present invention further relates to these compounds attached to antibodies.
- Monoclonal antibodies are immunoglobulins of well-defined chemical structure. A characteristic feature of monoclonal antibodies is reproducibility of function and high specificity. Diagnostic methods are adversely affected unless substantially all of the compound used for labeling is securely attached to the targeting agent. Any of the labelling compound that does not attach to the targeting agent can create an undesirable background. If radiometals are used, they can disseminate in the body and have the potential of doing damage.
- U.S. Patent 4,454,106 relates to metal chelate conjugated monoclonal antibodies for diagnostic and therapeutic techniques.
- the chelating agent is derived from diethylenetriaminepentaacetic acid (DTPA) , and the conjugate is substantially free of adventitiously bound metal.
- the chelate conjugated to the monoclonal antibody is a derivative of DTPA bonded to an organic functional group which serves to link the DTPA chelate to the monoclonal antibody.
- the foregoing objects and others are accomplished in accordance with the present invention, generally speaking, by providing bifunctionai chelating agents having a tris-catechol structure and a method for preparing the same, wherein these agents are useful for sequestering radioactive metals (radionuclides) and for providing a means for covalently attaching these radionuclides to a macromolecule, such as an antibody.
- the present invention further encompasses therapeutic and diagnostic techniques which employ the bifunctionai chelating agents in the form of radiometal chelate conjugated monoclonal antibodies.
- the present invention provides bifunctionai chelating agents designed to sequester radioactive metals and to provide a means for covalently attaching these radionuclides to a macromolecule.
- the macromolecule is a tumor-seeking monoclonal antibody
- the radioactive conjugate can be used in patients for cancer diagnosis or therapy.
- the chelating agents of the present invention bind metals through three deprotonated 2,3- dihydroxyterephthalate moieties, known to have a much greater affinity for small, highly charged ions, such as Fe(III) and Ga(III), than for divalent ions, such as Ca(II) or Cu(II) .
- two of the binding subunits are endocyclic within a 26 me bered ring, a feature which should enhance the kinetic stability of the metal complex.
- the bifunctionai chelating agents of the present invention are represented by the formulas 1 and la shown below. Notable features of the chelating agents of the present invention include the 2,3-dihydroxyterephthalate binding subunits and the presence of a functionalized sidearm which allows the chelate to be covalently attached to a monoclonal antibody through, for example, a thiourea linkage.
- the disuccinimido-2,3- dibenzyloxyterephthalate 2 is reacted with two equivalents of the ligand tris(2-aminoethyl)amine (TREN) in the presence of iron (III) to give the metal complex 3.
- TREN tris(2-aminoethyl)amine
- This reactive intermediate may be reacted with 1- amino-2-(p-N0 2 -Benzyl)ethane to give the derivatized complexes 4a, .
- the reactive alkylamine is then protected with acetic anhydride to give 5a, b and then the aromatic amine reduced to provide the aniline metal complex derivative 6 that is subsequently demetalated to provide the amino ligand 1 which may be reacted with thiophosgene to give the isothiocyanate ligand la.
- Both 1, la are useful for linkage of the ligand to proteins, such as antibodies, by carbohydrate modification methods for 1 and by direct reaction with amino acid residues with la.
- the present invention employs metal chelate conjugated monoclonal antibodies for diagnostic and therapeutic techniques, particularly in vivo.
- the metal may be radioactive, exhibit fluorogenic properties, exhibit paramagnetic properties or the like.
- Monoclonal antibodies are immunoglobulins of well- defined chemical structure, in contrast to polyclonal antibodies which are heterogeneous mixtures. Reproducibility of function cannot be controlled for either polyclonal or autologous antibodies, whereas unaltered function is characteristic to monoclonal antibodies. Experimental techniques for obtaining monoclonal antibodies have been extensively discussed. A useful text is Monoclonal Antibodies (R.H. Kennett, T.J. McKearn & K.B. Bechtol eds. 1980). See also Koprowski et al. U.S. Patent 4,196,265 which is incorporated herein by reference. Any monoclonal antibody which exhibits cell binding or antigen binding at the cell targeted for therapy or which is catabolized to inside the cell membrane can be employed. The selection and production of suitable monoclonal antibodies is within the skill of the art.
- the antibodies are generally maintained in an aqueous solution that contains an ionic compound.
- a physiologic normal saline solution is very often employed and is widely available.
- Other ionic solutions such as those containing sodium or potassium phosphate, sodium bicarbonate and the like, are known in the art and may also be employed.
- the invention contemplates an in vivo therapeutic procedure in which radiometal chelate conjugated monoclonal antibodies are introduced into the body and allowed to concentrate in the target region.
- radiometal isotopes which form stable complexes with the chelating agents of the present invention and emit cytotoxic beta or positron particles, or Auger electrons.
- Useful beta or positron particle emitting isotopes include but are not limited to Sc-46, Sc-47, Sc-48, Ga-66, and Ga-68.
- the choice of radionuclide to be used depends on the purpose of the use, whether diagnosis of therapy, and is within the skill of the art.
- the therapeutic effect occurs when the conjugates are near or in contact with and bind to the targeted cells. Cell death, it is believed, is a direct or indirect result of the radiation event of the radiometal which is positioned in close proximity to the cell.
- the benefits of this aspect of the invention are several.
- the high specificity of the conjugated monoclonal antibody minimizes the total radiation dosage. Only enough radiation for the target cells need be employed.
- radiometal chelates generally are cleared rapidly from the body should the conjugated antibody be disrupted.
- the isotope can be short-lived and the affinity constant by which the isotope that is retained in the chelate is very high resulting in a stably bound metal.
- the amount of radiometal employed is minimized, the radiation hazard to persons preparing and administering the radiometal chelate conjugated antibody is also minimized.
- tissue damage or whole body dose during therapy are markedly reduced as compared to that from presently employed methods of radiation therapy such as isotope implants, external radiation therapy such as isotope implants, external radiation therapy, and immunoradiotherapy employing iodine-131 labeled polyclonal or autologous antibodies. Additionally, both biological and physical half-lives of the targeting radiobiological may now be controlled, minimizing whole body radiation effects. Since radiation is targeted specifically to cell types (e.g. neoplastic cells), a therapeutic dose is delivered specifically to malignant cells, either localized or metastasized.
- the present invention employs the metal chelate conjugated monoclonal antibody containing a positron emitting radiometal to treat cellular disorders. It is desirable in most applications that the radiometal have a half-life of less than about four days and decay rapidly to a stable isotope once the alpha particle is emitted.
- the preferred isotopes employed in the present invention are Ga-66 and 68. Particularly preferred is Ga-66 with a half life of 9.4 hr.
- the present invention contemplates in vivo diagnostic procedure which comprises introducing a metal chelate conjugated monoclonal antibody into the body, allowing sufficient time for the conjugate to localize and identifying the degree and location of localization, if any.
- the present invention also contemplates in vitro analytical procedures employing a chelate conjugated monoclonal antibody.
- the conjugated antibody of the present invention is substantially free of adventitiously or weakly chelated metal.
- isotopes useful for diagnostic purposes form stable complexes with the chelate of the present invention.
- Gamma or positron emitting isotopes are particularly useful for imaging target sites both in vivo and in vitro in radioimaging procedures. Examples of gamma or positron emitting isotopes include Tc-99m, Ga-
- Tc-99m in In-Ill are preferred.
- Sc-43, S ⁇ -44, Fe-52, Co-55 and Ga-66,68 may be employed.
- lanthanides may be employed, in particular, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm and Yb.
- Paramagnetic diagnostic techniques would typically employ the stable iron isotopes such as Fe-54, Fe-56, Fe-
- the metal chelate conjugated antibodies of this invention can be administered in vivo in any suitable pharmaceutical carrier.
- a physiologic normal saline solution can appropriately be employed.
- the carrier will include a minor amount of carrier protein such as human serum albumin to stabilize the antibody.
- concentration of metal chelate conjugated antibodies within the solution will be a matter of choice. Levels of about 0.5 mg per ml are readily attainable but the concentrations may vary considerably depending upon the specifics of any given application. Appropriate concentrations of biologically active materials in a carrier are routinely determined in the art.
- the effective dose of radiation or metal content to be utilized for any application will also depend upon the particulars of that application.
- the dose will depend, inter alia, upon tumor burden, accessibility and the like.
- the use of metal chelate conjugated antibodies for diagnostic purposes will depend, inter alia, upon the sensing apparatus employed, the location of the site to be examined and the like.
- the circulating antigens can be removed prior to the treatment.
- Such removal of antigens can be removed prior to treatment.
- Such removal of antigens can be accomplished, for example, by the use of unlabeled antibodies, or by plasmapheresis in which the patient's serum is treated to remove antigens.
- the present invention also contemplates the above- described chelating agents attached to macromolecules, such as antibodies.
- the antibody anti-Tac is known to localize in adult t-cell leukemias.
- the antibody B72.3 localizes on the surface of colon cancer cells, and the antibody B-l localizes in B-cell lymphomas.
- FeCl 3 (.378 g, 2.32 mmol in ca. 30 ml DMF) were added simultaneously. The resulting dark reddish brown solution was transferred to addition funnel A and DMF added to make the total volume 250 ml.
- Triethylamine (0.27 ml, ca. 1.9 mmol) was added to neutral ferric complex 4a (0.36 g, .36 mmol) suspended in 10 ml MeOH. The resulting deep burgundy solution was stirred 15 minutes, then evaporated to dryness. The solid was redissolved in methanol (10 ml) and again evaporated to dryness. The solid was vacuum dried 48 hours to give 0.4 g (0.33 mmol).
- Neutral complex 5a (0.15 g, .14 mmol) was suspended in 5 ml CHgOH and stirred while triethylamine (0.12 ml, 0.086 g, .85 mmol) was added. The resulting burgundy solution was evaporated to dryness, redissolved in 20 ml methanol and again evaporated to dryness. The solid was taken up in ca. 1 ml methanol, precipitated by the addition of diethyl ether, and collected on a fine glass frit. The solid was vacuum dried to give 0.19 g (.14 mmol, 95%) of the triethylammonium salt 5b. Elemental Analysis: Calc for
- the pH of the solution was adjusted to 7.4, and was then transferred via syringe to a 50 ml 3 neck flask containing 250 g 10% Pd/C (saturated with H 2 ) . Hydrogenation at atmospheric pressure was complete in 7-8 hours, as evidenced by the analytical HPLC (conditions #2) which showed the complete conversion of starting material (RT 10.4) to a single product (RT 9.6).
- the catalyst was removed by filtration and washed with water (10 ml) (Buchner) . To the filtrate was added Na 2 EDTA 21 ⁇ 0 (1.41 g, 3.8 mmol, 10 eq) and glacial acetic acid (12 ml) . The solution was stirred 2 hours at room temperature, then left to stand at room temperature 12 hours.
- the precipitate was filtered and washed with 15 ml 0.1 M AcOH.
- the filtrate was diluted to 100 ml with 0.1 M AcOH and purified by HPLC using a Gilson autoprep system and conditions #3. The fraction between 10.5 and 12 minutes was collected and evaporated to dryness.
- the brown solid (ca. 300 mg) was taken up in 140 ml boiling absolute ethanol and cooled to room temperature. Et 2 0 (125 ml) was added and the solution cooled to 4C. The resulting solid was collected, washed with Eto and dried to give 0.19 g (0.2 mmol, 52%) of the neutral tris(catecholate) ligand.
Abstract
Bifunctional chelating agents are designed to sequester certain radioactive metals, such as gallium (III) isotopes, and to provide a means for covalently attaching these radionuclides to macromolecules, such as monoclonal antibodies. These chelating agents may be used in various therapeutic and diagnostic methods, such as in radioimaging and positron emission tomography.
Description
DERIVATIZED TRIS-CATECHOL CHELATING AGENTS BACKGROUND OF THE INVENTION Field of the Invention
The present invention relates to novel "bifunctionai" chelating agents. More specifically, the present invention relates to bifunctionai chelating agents which are designed to sequester certain radioactive metals and to provide a means for covalently attaching these radionuclides to a macromolecule, such as an antibody. The invention further relates to methods for preparing these compounds as well as methods of using these compounds in radioimmunoimaging, positron emission tomography and in vivo treatment. The present invention further relates to these compounds attached to antibodies.
Description of Related Art
Effective therapeutic methods for the treatment of cellular disorders such as cancer have been the object of intensive research. Conventional therapy employs surgery, radiation and chemotherapy. Each of these methods suffers a serious drawback in that it is not highly selective between healthy and cancerous cells. In order to be effective, these methods kill or remove large amounts of healthy tissue. Furthermore, chemotherapy adversely affects the immune system so that death or serious illness often arises from fungal, bacterial or viral infections.
The development of monoclonal antibodies has opened the possibility of selectively delivering therapeutic agents or diagnostic agents to specific target cells. Monoclonal antibodies are immunoglobulins of well-defined chemical structure. A characteristic feature of monoclonal antibodies is reproducibility of function and high specificity.
Diagnostic methods are adversely affected unless substantially all of the compound used for labeling is securely attached to the targeting agent. Any of the labelling compound that does not attach to the targeting agent can create an undesirable background. If radiometals are used, they can disseminate in the body and have the potential of doing damage.
U.S. Patent 4,454,106 relates to metal chelate conjugated monoclonal antibodies for diagnostic and therapeutic techniques. The chelating agent is derived from diethylenetriaminepentaacetic acid (DTPA) , and the conjugate is substantially free of adventitiously bound metal. The chelate conjugated to the monoclonal antibody is a derivative of DTPA bonded to an organic functional group which serves to link the DTPA chelate to the monoclonal antibody.
Although the concept of attaching radionuclides to monoclonal antibodies with bifunctionai chelates has been employed in some conventional methods, most conventional methods have utilized polyaminocarboxylates to coordinate the radionuclide. However, these chelators do not exhibit especial selectivity in their chelation of trivalent radiometals so trace divalent metal impurities may interfere in radiolabeling protocols. An increase in selectivity is desired and is of practical utility in that it would reduce the importance of the purity of radioactive metal ion solutions used for radiolabeling, thus lowering costs, and would increase stability of radiopharmaceutical preparations in vivo. SUMMARY OF THE INVENTION
It is an object of the present invention to provide novel chelating agents which overcome the above-noted problems and which sequester radioactive metals and
provide a means for covalently attaching the radionuclides to macromolecules.
It is another object of the present invention to provide a method for preparing bifunctionai chelating agents.
It is a further object of the present invention to provide diagnostic and therapeutic techniques which employ these bifunctionai chelating agents in the form of radiometal chelate conjugated monoclonal antibodies. The foregoing objects and others are accomplished in accordance with the present invention, generally speaking, by providing bifunctionai chelating agents having a tris-catechol structure and a method for preparing the same, wherein these agents are useful for sequestering radioactive metals (radionuclides) and for providing a means for covalently attaching these radionuclides to a macromolecule, such as an antibody. The present invention further encompasses therapeutic and diagnostic techniques which employ the bifunctionai chelating agents in the form of radiometal chelate conjugated monoclonal antibodies.
Further scope of the applicability of the present invention will become apparent from the detailed description and drawings provided below. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides bifunctionai chelating agents designed to sequester radioactive metals and to provide a means for covalently attaching these radionuclides to a macromolecule. When the macromolecule is a tumor-seeking monoclonal antibody, the radioactive conjugate can be used in patients for cancer diagnosis or therapy. The chelating agents of the present invention bind metals through three deprotonated 2,3- dihydroxyterephthalate moieties, known to have a much greater affinity for small, highly charged ions, such as Fe(III) and Ga(III), than for divalent ions, such as Ca(II) or Cu(II) . In addition, two of the binding subunits are endocyclic within a 26 me bered ring, a feature which should enhance the kinetic stability of the metal complex.
The bifunctionai chelating agents of the present invention are represented by the formulas 1 and la shown below. Notable features of the chelating agents of the present invention include the 2,3-dihydroxyterephthalate binding subunits and the presence of a functionalized sidearm which allows the chelate to be covalently attached to a monoclonal antibody through, for example, a thiourea linkage.
1 R=NH2 la R=NCS
The above chelating agents are prepared in accordance with the present invention by derivatizing an intermediate 3 (below) in accordance with the synthetic procedures described for synthesizing macrobicyclic tris- catechol ligand in McMurry et al, J. Am. Chem. Soc.. Vol. 109, pp. 3451-3453 (1987).
The synthetic scheme for the chelating agents of the present invention is summarized below.
As shown in the scheme above, the disuccinimido-2,3- dibenzyloxyterephthalate 2 is reacted with two equivalents of the ligand tris(2-aminoethyl)amine (TREN) in the presence of iron (III) to give the metal complex 3. This reactive intermediate may be reacted with 1- amino-2-(p-N02-Benzyl)ethane to give the derivatized complexes 4a, . The reactive alkylamine is then protected with acetic anhydride to give 5a, b and then the aromatic amine reduced to provide the aniline metal complex derivative 6 that is subsequently demetalated to provide the amino ligand 1 which may be reacted with thiophosgene to give the isothiocyanate ligand la. Both 1, la are useful for linkage of the ligand to proteins, such as antibodies, by carbohydrate modification methods for 1 and by direct reaction with amino acid residues with la.
The present invention employs metal chelate conjugated monoclonal antibodies for diagnostic and therapeutic techniques, particularly in vivo. The metal may be radioactive, exhibit fluorogenic properties, exhibit paramagnetic properties or the like.
Monoclonal antibodies are immunoglobulins of well- defined chemical structure, in contrast to polyclonal antibodies which are heterogeneous mixtures. Reproducibility of function cannot be controlled for either polyclonal or autologous antibodies, whereas unaltered function is characteristic to monoclonal antibodies. Experimental techniques for obtaining monoclonal antibodies have been extensively discussed. A useful text is Monoclonal Antibodies (R.H. Kennett, T.J. McKearn & K.B. Bechtol eds. 1980). See also Koprowski et al. U.S. Patent 4,196,265 which is incorporated herein by reference. Any monoclonal
antibody which exhibits cell binding or antigen binding at the cell targeted for therapy or which is catabolized to inside the cell membrane can be employed. The selection and production of suitable monoclonal antibodies is within the skill of the art.
The antibodies are generally maintained in an aqueous solution that contains an ionic compound. A physiologic normal saline solution is very often employed and is widely available. Other ionic solutions, such as those containing sodium or potassium phosphate, sodium bicarbonate and the like, are known in the art and may also be employed.
The invention contemplates an in vivo therapeutic procedure in which radiometal chelate conjugated monoclonal antibodies are introduced into the body and allowed to concentrate in the target region. There are a variety of radiometal isotopes which form stable complexes with the chelating agents of the present invention and emit cytotoxic beta or positron particles, or Auger electrons. Useful beta or positron particle emitting isotopes include but are not limited to Sc-46, Sc-47, Sc-48, Ga-66, and Ga-68. The choice of radionuclide to be used depends on the purpose of the use, whether diagnosis of therapy, and is within the skill of the art. The therapeutic effect occurs when the conjugates are near or in contact with and bind to the targeted cells. Cell death, it is believed, is a direct or indirect result of the radiation event of the radiometal which is positioned in close proximity to the cell.
The benefits of this aspect of the invention are several. First, the high specificity of the conjugated monoclonal antibody minimizes the total radiation dosage.
Only enough radiation for the target cells need be employed. In addition, radiometal chelates generally are cleared rapidly from the body should the conjugated antibody be disrupted. The isotope can be short-lived and the affinity constant by which the isotope that is retained in the chelate is very high resulting in a stably bound metal. Finally, since the amount of radiometal employed is minimized, the radiation hazard to persons preparing and administering the radiometal chelate conjugated antibody is also minimized.
Because of the properties of the radiometal chelate conjugated monoclonal antibody employed by the present invention, tissue damage or whole body dose during therapy are markedly reduced as compared to that from presently employed methods of radiation therapy such as isotope implants, external radiation therapy such as isotope implants, external radiation therapy, and immunoradiotherapy employing iodine-131 labeled polyclonal or autologous antibodies. Additionally, both biological and physical half-lives of the targeting radiobiological may now be controlled, minimizing whole body radiation effects. Since radiation is targeted specifically to cell types (e.g. neoplastic cells), a therapeutic dose is delivered specifically to malignant cells, either localized or metastasized. The ability of radiometal chelate conjugated monoclonal antibody to provide an effective dose or therapeutic radiation specifically to metastasized cells is also unique and singularly useful for cancer therapy. In one of its particularly preferred aspects, the present invention employs the metal chelate conjugated monoclonal antibody containing a positron emitting radiometal to treat cellular disorders. It is desirable
in most applications that the radiometal have a half-life of less than about four days and decay rapidly to a stable isotope once the alpha particle is emitted. The preferred isotopes employed in the present invention are Ga-66 and 68. Particularly preferred is Ga-66 with a half life of 9.4 hr.
In another embodiment, the present invention contemplates in vivo diagnostic procedure which comprises introducing a metal chelate conjugated monoclonal antibody into the body, allowing sufficient time for the conjugate to localize and identifying the degree and location of localization, if any. The present invention also contemplates in vitro analytical procedures employing a chelate conjugated monoclonal antibody. The conjugated antibody of the present invention is substantially free of adventitiously or weakly chelated metal.
A variety of isotopes useful for diagnostic purposes form stable complexes with the chelate of the present invention. Gamma or positron emitting isotopes are particularly useful for imaging target sites both in vivo and in vitro in radioimaging procedures. Examples of gamma or positron emitting isotopes include Tc-99m, Ga-
67, Ga-68m or In-Ill. In the event that gamma camera images are desired, Tc-99m in In-Ill are preferred. For positron emission tomography, Sc-43, Sσ-44, Fe-52, Co-55 and Ga-66,68 may be employed. For fluorescence diagnostic techniques, lanthanides may be employed, in particular, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm and Yb. Paramagnetic diagnostic techniques would typically employ the stable iron isotopes such as Fe-54, Fe-56, Fe-
57 and Fe-58. Qualitative and quantitative measurements can be made with instrumentation sensitive to each of
these forms of emission, or properties (optical or magnetic) , available in the art.
The metal chelate conjugated antibodies of this invention can be administered in vivo in any suitable pharmaceutical carrier. As noted earlier, a physiologic normal saline solution can appropriately be employed. Often the carrier will include a minor amount of carrier protein such as human serum albumin to stabilize the antibody. The concentration of metal chelate conjugated antibodies within the solution will be a matter of choice. Levels of about 0.5 mg per ml are readily attainable but the concentrations may vary considerably depending upon the specifics of any given application. Appropriate concentrations of biologically active materials in a carrier are routinely determined in the art.
The effective dose of radiation or metal content to be utilized for any application will also depend upon the particulars of that application. In treating tumors, for example, the dose will depend, inter alia, upon tumor burden, accessibility and the like. Somewhat similarly, the use of metal chelate conjugated antibodies for diagnostic purposes will depend, inter alia, upon the sensing apparatus employed, the location of the site to be examined and the like. In the event that the patient has circulating antigen in addition to those located at the site, the circulating antigens can be removed prior to the treatment. Such removal of antigens can be removed prior to treatment. Such removal of antigens can be accomplished, for example, by the use of unlabeled antibodies, or by plasmapheresis in which the patient's serum is treated to remove antigens.
The present invention also contemplates the above- described chelating agents attached to macromolecules, such as antibodies. For example, the antibody anti-Tac is known to localize in adult t-cell leukemias. The antibody B72.3 localizes on the surface of colon cancer cells, and the antibody B-l localizes in B-cell lymphomas.
The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.
Template synthesis of 4a
Disuccinimido-2,3-dibenzyloxyterephthalate (4.0 g,
6.99 mmol) was dissolved in 200 ml EtOAc and hydrogenolyzed under 1 atm H2 in the presence of 1 g 5% PD-C (2 hours) . The resulting suspension of product and catalyst was filtered onto #42 paper using a Buchner funnel, and the filtrate was evaporated to recover the small amount of soluble product. Using vacuum filtration, the product disuccinimido-2,3- dihydroxyterephthalate was washed into a 250 ml RB flask with 200 ml DMF and placed under an argon atmosphere.
Triethylamine (6 ml, ca. 43 mmol) and a DMF solution of
FeCl3(.378 g, 2.32 mmol in ca. 30 ml DMF) were added simultaneously. The resulting dark reddish brown solution was transferred to addition funnel A and DMF added to make the total volume 250 ml.
To addition funnel B was added 250 ml dry DMF and TREN (0.676 g, 4.64 mmol). The contents of addition funnels A and B were added to 800 ml DMF over 6 hours at room temperature and the reaction subsequently stirred 14 hours. High pressure liquid chromatography (HPLC) assay (conditions #2) showed essentially one peak, the mono- active ester 3, at 10.27 minutes. To this solution was
added 3-(para-nitrophenyl)propylamine hydrochloride (0.7 g, 3.2 mmol) and triethylamine (1 ml, ca, 7 mmol). The solution was stirred for 12 hours (HPLC retention time of product, 11.19 minutes), and the DMF evaporated to dryness. Aqueous ammonium acetate (0.01 M, 350 ml) was added and the pH adjusted to 9.7 with NH4OH. The solution was stirred 12 hours and the insoluble materials removed by filtration. The pH of the filtrate was adjusted to 6.8 with glacial acetic acid and the volume diluted to 400 ml with 0.01 M AcONH4. Purification was achieved by HPLC using a Waters Delta Prep and a Waters Delta Pak preparative C-18 reverse phase column (30 x 300 mm, 15 micro spherical packing, 100 A pore size) with a mobile phase of A = H20 and B = MeOH (both 0.01 M AcONH4) . In a typical run, 10 ml of the above solution (D) was loaded and the products eluted with a 0-100% B (10%/min) gradient at 40 ml/min. The fraction eluting between 8.7 - 9.7 minutes was collected. The procedure was repeated until all crude material was purified. The aqueous solutions of product were evaporated to dryness and redissolved in ca. 125 ml H20. The solution was acidified to pH 3.05 with glacial acetic acid, resulting in a blackish precipitate (the neutral ferric complex) , which was collected on a medium frit and washed with ca. 60 ml H20 and dried to give 0.988g (1.03 mmol, 45%). A summary of the HPLC results is provided below in Table 1.
ID curve
IR (nujol, cm'1) 3380(br), 3200, 1606(br), 1545, 1460, 1363, 1340, 1320, 1229, 1196(s), 730(m), 651(m)
Conversion to the triethylammonium salt 4b
Triethylamine (0.27 ml, ca. 1.9 mmol) was added to neutral ferric complex 4a (0.36 g, .36 mmol) suspended in 10 ml MeOH. The resulting deep burgundy solution was stirred 15 minutes, then evaporated to dryness. The solid was redissolved in methanol (10 ml) and again evaporated to dryness. The solid was vacuum dried 48 hours to give 0.4 g (0.33 mmol).
Elemental Analysis: Calc. for [FeLH]2-[(Et3NH+)2]- 2H20 FeC57H72N18014: C,54.76; H,6.85; N,13.44; Fe,4.47. Found C,54.71; H,7.02; N,13.47? Fe,4.21. Synthesis of the acetaroide 5a
Neutral ferric complex 4a (0.497 g, 0.49 mmol) was dissolved in 8 ml anhydrous DMF under argon by the
addition of Et3N (.41 ml, ca. .3g, 2.9 mmol, 6 equiv.) was added and the reaction stirred 75 minutes. HPLC (conditions #2, Gilson) show no starting material (RT 11.07 min) and a single product (RT 10.37 min) . The DMF was evaporated to give an oil, to which 10 ml H20 was added. Glacial acetic acid was added to precipitate the ferric complex, which was collected on a fine glass frit, washed with water and dried to give 0.45 g (0.43 mmol, 87%). Preparation of Et3NH salt of acetamide 5b
Neutral complex 5a (0.15 g, .14 mmol) was suspended in 5 ml CHgOH and stirred while triethylamine (0.12 ml, 0.086 g, .85 mmol) was added. The resulting burgundy solution was evaporated to dryness, redissolved in 20 ml methanol and again evaporated to dryness. The solid was taken up in ca. 1 ml methanol, precipitated by the addition of diethyl ether, and collected on a fine glass frit. The solid was vacuum dried to give 0.19 g (.14 mmol, 95%) of the triethylammonium salt 5b. Elemental Analysis: Calc for
[Fe(C47H5ON10O15]3[CβH1βN+]3 31^0 :C,57.51; H,7.28 N,13.41; Fe,4.11. Found: C,55.31; H,7.43; N,12.90; Fe,3.96. Reduction to aniline and demetallation to σive 1 Neutral ferric complex 5a (0.4 g, .38 mmol) was suspended in 10 ml H20 and solubilized by the addition of NaOH (1.2 ml 1M NaOH, 1.1 mmol). The pH of the solution was adjusted to 7.4, and was then transferred via syringe to a 50 ml 3 neck flask containing 250 g 10% Pd/C (saturated with H2) . Hydrogenation at atmospheric pressure was complete in 7-8 hours, as evidenced by the analytical HPLC (conditions #2) which showed the complete conversion of starting material (RT 10.4) to a single
product (RT 9.6). The catalyst was removed by filtration and washed with water (10 ml) (Buchner) . To the filtrate was added Na2EDTA 21^0 (1.41 g, 3.8 mmol, 10 eq) and glacial acetic acid (12 ml) . The solution was stirred 2 hours at room temperature, then left to stand at room temperature 12 hours. The precipitate was filtered and washed with 15 ml 0.1 M AcOH. The filtrate was diluted to 100 ml with 0.1 M AcOH and purified by HPLC using a Gilson autoprep system and conditions #3. The fraction between 10.5 and 12 minutes was collected and evaporated to dryness. The brown solid (ca. 300 mg) was taken up in 140 ml boiling absolute ethanol and cooled to room temperature. Et20 (125 ml) was added and the solution cooled to 4C. The resulting solid was collected, washed with Eto and dried to give 0.19 g (0.2 mmol, 52%) of the neutral tris(catecholate) ligand. 1H NMR (D2) , pD=9.5): 7.07(d,2H,J=7.9Hz) , 6.925(d,1H,J=8.5Hz) 6.725(d,2H,J=8.1Hz) 6.651(br.s.,4H)
6.575(d,2H,J=8.6Hz) 3.398(br.S.,6H) , 3.291(br.S.,6H) 3.093(br.t.,2H) 2.731(br.s.,6H) 2.581(br.s.,6H)
2.449(br.t.,2H) , 1.809(m,2H), 1.598(s,3H) Synthesis of la
Compound 1 (27.8 mg, 26.1 μmol) was dissolved in 0.100 M NaOH (.813 mL) . To this golden solution was added Cl2CS (192 μL of a 0.17M CHC13 solution). The reaction was stirred vigorously for 3 minutes, during which time a greenish gray precipitate formed. The precipitate was concentrated by centrifugation, the
supernatent removed, and the solid washed with distilled water. After vacuum drying, 25 mg of product was obtained. IR (nujol) 3300 (m) , 2080(s) .
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.
Claims
1. A compound of the formula:
wherein R is - Ha or -NCS.
2. A compound of the formula:
wherein R is -NH2 or -NCS, said compound being complexed with a radiometal isotope.
3. A pharmaceutical composition comprising a compound of the formula:
4. Use of a solution of the radiometal chelate conjugated antibodies of claim 3 specific for a target cell for an in vivo diagnostic method for the treatment of cellular disorders wherein said solution is introduced into body fluid.
5. Use of a solution of the radiometal chelate conjugated antibodies of claim 3 for an in vitro diagnostic method which comprises introducing into a test medium said solution and quantifying the specifically bound portion of said conjugate.
6. Use according to claim 5 wherein quantifying is conducted by using radioimmunoimaging or positron emission tomography.
7. A method for preparing final product compounds of the formula:
wherein R is -NI^ or -NCS, which method comprises the steps of: reacting disuccinomido-2 ,3-dibenzyloxyterephthalate with tris(2-aminoethyl)amine in the presence of iron (III) to form an intermediate metal complex; reacting said intermediate metal complex with 1- amino-2-(p-N02-Benzyl)ethane to form derivatized intermediate complexes; reacting said derivatized intermediate complexes with acetic anhydride to form aromatic amine compounds of the following formula:
I3
wherein X is H or EtgNH; reducing said aromatic amine compounds to form an aniline metal complex derivative of the formula:
; and demetalating said aniline metal complex derivative o form said final product compound.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62800290A | 1990-12-17 | 1990-12-17 | |
US628,002 | 1990-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992011039A1 true WO1992011039A1 (en) | 1992-07-09 |
Family
ID=24517011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/009153 WO1992011039A1 (en) | 1990-12-17 | 1991-12-12 | Derivatized tris-catechol chelating agents |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU9163491A (en) |
WO (1) | WO1992011039A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000048991A1 (en) * | 1999-02-18 | 2000-08-24 | The Regents Of The University Of California | Salicylamide-lanthanide complexes for use as luminescent markers |
WO2000048990A1 (en) * | 1999-02-18 | 2000-08-24 | The Regents Of The University Of California | Phthalamide-lanthanide complexes for use as luminescent markers |
US8173800B2 (en) | 2006-08-15 | 2012-05-08 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
US8507199B2 (en) | 2007-01-25 | 2013-08-13 | Lumiphore, Inc. | Multi-color time resolved fluorophores based on macrocyclic lanthanide complexes |
US8551453B2 (en) | 2003-12-30 | 2013-10-08 | The Regents Of The University Of California | Aromatic triamide-lanthanide complexes |
WO2013187971A2 (en) * | 2012-05-31 | 2013-12-19 | The Regents Of The University Of California | Macrocycles |
US9273059B2 (en) | 2009-08-24 | 2016-03-01 | Lumiphore, Inc. | Macrocyclic HOPO chelators |
US9556122B2 (en) | 2006-07-10 | 2017-01-31 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4732974A (en) * | 1986-03-05 | 1988-03-22 | Mallinckrodt, Inc. | Metal ion labeling of carrier molecules |
-
1991
- 1991-12-12 AU AU91634/91A patent/AU9163491A/en not_active Abandoned
- 1991-12-12 WO PCT/US1991/009153 patent/WO1992011039A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4732974A (en) * | 1986-03-05 | 1988-03-22 | Mallinckrodt, Inc. | Metal ion labeling of carrier molecules |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF AMERICAN CHEMICAL SOCIETY, Volume 109, No. 11, issued November 1987, (USA), T.J. MCMURRAY et al., "Template and Stepwise Synthesis of a Macrobicyclic Catechoylamide Ferric Ion Sequestering Agent", see pages 3451-3453. * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000048990A1 (en) * | 1999-02-18 | 2000-08-24 | The Regents Of The University Of California | Phthalamide-lanthanide complexes for use as luminescent markers |
US6406297B1 (en) | 1999-02-18 | 2002-06-18 | The Regents Of The University Of California | Salicylamide-lanthanide complexes for use as luminescent markers |
US6515113B2 (en) | 1999-02-18 | 2003-02-04 | The Regents Of The University Of California | Phthalamide lanthanide complexes for use as luminescent markers |
JP2003523312A (en) * | 1999-02-18 | 2003-08-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Phthalamide-lanthanide complexes for use as luminescent markers |
US6864103B2 (en) | 1999-02-18 | 2005-03-08 | The Regents Of The University Of California | Phthalamide-lanthanide complexes for use as luminescent markers |
US7018850B2 (en) | 1999-02-18 | 2006-03-28 | The Regents Of The University Of California | Salicylamide-lanthanide complexes for use as luminescent markers |
US7404912B2 (en) | 1999-02-18 | 2008-07-29 | The Regents Of The University Of California | Salicylamide-lanthanide complexes for use as luminescent markers |
US7442558B2 (en) | 1999-02-18 | 2008-10-28 | The Regents Of The University Of California | Phthalamide-lanthanide complexes for use as luminescent markers |
JP4819223B2 (en) * | 1999-02-18 | 2011-11-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Phthalamide-lanthanide complexes for use as luminescent markers |
WO2000048991A1 (en) * | 1999-02-18 | 2000-08-24 | The Regents Of The University Of California | Salicylamide-lanthanide complexes for use as luminescent markers |
US8551453B2 (en) | 2003-12-30 | 2013-10-08 | The Regents Of The University Of California | Aromatic triamide-lanthanide complexes |
US9556122B2 (en) | 2006-07-10 | 2017-01-31 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
US8173800B2 (en) | 2006-08-15 | 2012-05-08 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
US8729258B2 (en) | 2006-08-15 | 2014-05-20 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
US8507199B2 (en) | 2007-01-25 | 2013-08-13 | Lumiphore, Inc. | Multi-color time resolved fluorophores based on macrocyclic lanthanide complexes |
US9273059B2 (en) | 2009-08-24 | 2016-03-01 | Lumiphore, Inc. | Macrocyclic HOPO chelators |
US10352938B2 (en) | 2009-08-24 | 2019-07-16 | Lumiphore, Inc. | Macrocyclic HOPO chelators |
WO2013187971A2 (en) * | 2012-05-31 | 2013-12-19 | The Regents Of The University Of California | Macrocycles |
WO2013187971A3 (en) * | 2012-05-31 | 2014-04-03 | The Regents Of The University Of California | Macrocycles |
US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
Also Published As
Publication number | Publication date |
---|---|
AU9163491A (en) | 1992-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0587555B1 (en) | A bifunctional dtpa-type ligand | |
EP0627939B1 (en) | Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy | |
AU596590B2 (en) | Method of forming a metal chelate protein conjugate | |
EP0452858B1 (en) | Metal complexes of acid adducts to dioxime ligands useful in labelling proteins and other amine-containing compounds | |
JP2604796B2 (en) | 10-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | |
US5284644A (en) | Functionalized polyamine chelants and rhodium complexes thereof for conjugation to antibodies | |
JP6211066B2 (en) | Radiopharmaceutical complex | |
US5099069A (en) | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate | |
JPH0791317B2 (en) | Carrier-Metal ion labeling of molecules | |
CN110496233B (en) | SPECT imaging agent, marked precursor thereof, preparation method, composition and application thereof | |
WO1992011039A1 (en) | Derivatized tris-catechol chelating agents | |
GB2122641A (en) | Metal chelate conjugated monoclonal antibodies, wherein the metal is an ??? emitter | |
EP0484989B1 (en) | Polysubstituted diethylenetriamine chelates for forming a metal-chelate-protein conjugate | |
US6696551B1 (en) | 225Ac-HEHA and related compounds, methods of synthesis and methods of use | |
Kothari et al. | 99mTc (CO) 3-VIP analogues: preparation and evaluation as tumor imaging agent | |
WO2000059896A1 (en) | 225Ac-HEHA AND RELATED COMPOUNDS, METHODS OF SYNTHESIS AND METHODS OF USE | |
AU2018237784B2 (en) | Isomerically pure 18F-labelled tetrahydrofolates | |
GB2214507A (en) | 2,3-dithiosuccinic acid derivative and their use | |
Gansow et al. | Metal chelate conjugated monoclonal antibodies, wherein the metal is an α emitter | |
JPS59106426A (en) | Radioactive diagnostic for nucleomedical use containing polymeric compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |